We further identify SIRT1 as a negative regulator of LT and TNFα, and implicate SIRT1 as the miR target responsible for the miR-132-mediated aberrant pro-inflammatory B cell cytokine responses observed in patients with MS. Here, SIRT1 is linked to myeloid sarcoma.